Zum Hauptinhalt springen Zur Suche springen Zur Hauptnavigation springen
Herzlich Willkommen!
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
ISBN: 9781617375347
Sprache: Englisch
Seitenzahl: 290
Produktart: Kartoniert / Broschiert
Herausgeber: Fabbro, Doriano McCormick, Frank
Verlag: Humana Press
Veröffentlicht: 01.12.2010
Untertitel: From Inhibitors to Useful Drugs
Schlagworte: Proteomics biology cancer drug design drug discovery protein receptor structural biology

Das könnte Sie auch interessieren

Verwandte Artikel

Protein Tyrosine Kinases

214,00 CHF*